Global X Genomics & Biotechnology ETF (NASDAQ:GNOM) Short Interest Up 1,418.5% in June

Global X Genomics & Biotechnology ETF (NASDAQ:GNOM) saw a significant increase in short interest in June. As of June 30th, there was short interest totaling 114,234 shares, an increase of 1,418.5% from the June 15th total of 7,523 shares. Currently, 7.6% of the company’s shares are short sold. Based on an average trading volume of 53,894 shares, the days-to-cover ratio is currently 2.1 days.

Institutional Investors Weigh In On Global X Genomics & Biotechnology ETF

A number of large investors have recently modified their holdings of the stock. Bank of America Corp DE raised its stake in Global X Genomics & Biotechnology ETF by 67.8% in the first quarter. Bank of America Corp DE now owns 119,795 shares of the company’s stock worth $5,240,000 after buying an additional 48,394 shares in the last quarter. Wealth Management Partners LLC bought a new stake in Global X Genomics & Biotechnology ETF during the 1st quarter valued at approximately $244,000. Creative Financial Designs Inc. ADV boosted its position in Global X Genomics & Biotechnology ETF by 4.1% during the 4th quarter. Creative Financial Designs Inc. ADV now owns 12,124 shares of the company’s stock valued at $551,000 after acquiring an additional 481 shares in the last quarter. U.S. Capital Wealth Advisors LLC purchased a new position in shares of Global X Genomics & Biotechnology ETF during the 4th quarter worth approximately $575,000. Finally, IFP Advisors Inc grew its holdings in shares of Global X Genomics & Biotechnology ETF by 20.8% during the 3rd quarter. IFP Advisors Inc now owns 2,835 shares of the company’s stock worth $110,000 after acquiring an additional 489 shares during the period. Institutional investors own 56.95% of the company’s stock.

Global X Genomics & Biotechnology ETF Stock Performance

GNOM stock traded down $1.89 on Friday, reaching $56.65. The company’s stock had a trading volume of 33,529 shares, compared to its average volume of 14,357. The firm has a market cap of $86.67 million, a PE ratio of -24.21 and a beta of 1.16. The business has a fifty day simple moving average of $50.36 and a two-hundred day simple moving average of $47.61. Global X Genomics & Biotechnology ETF has a 12-month low of $34.04 and a 12-month high of $59.48.

Global X Genomics & Biotechnology ETF Dividend Announcement

The business also recently announced a dividend, which was paid on Tuesday, July 7th. Stockholders of record on Monday, June 29th were given a $0.0579 dividend. The ex-dividend date of this dividend was Monday, June 29th. Global X Genomics & Biotechnology ETF’s dividend payout ratio (DPR) is currently -27.35%.

About Global X Genomics & Biotechnology ETF

Complete Genomics, Inc is a life sciences company that has developed and commercialized a deoxyribonucleic acid (DNA) sequencing platform. Its complete genomics analysis platform (CGA) Platform, combines its human genome sequencing technology with its advanced informatics and data management software and its end-to-end, outsourced service model to provide its customers with data that is ready to be used for genome-based research. Its genome sequencing center combines a high-throughput sample preparation facility, a collection of its high-throughput sequencing instruments and a large- scale data center.